Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gentler embryo test could replace risky biopsy in IVF

NCT ID NCT07700602

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests a new, non-invasive method to check embryos for chromosome problems before IVF transfer. Instead of taking a cell sample, researchers analyze fluid the embryo grows in. The goal is to see if this test can predict which embryos will lead to a healthy pregnancy. The study includes women under 35 with good-quality embryos.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could make embryo genetic testing safer and more accessible by avoiding invasive biopsy.
What could go wrong
This is an observational study, not a treatment trial. The test may not reliably predict outcomes, and results may not apply to older patients or those with fewer embryos.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of women with good reproductive prognosis undergoing in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI) at My Duc Tan Binh Hospital and My Duc Phu Nhuan Hospital. Eligible participants are women aged 18 to 34 years with normal ovarian response, undergoing their first or second IVF cycle, and having at least one morphologically good-quality blastocyst available for frozen single embryo transfer. All participants receive standard IVF treatment according to routine clinical practice. Non-invasive preimplantation genetic testing for aneuploidy (NiPGT-A) is performed retrospectively using spent embryo culture media collected prior to embryo cryopreservation and is not used for clinical decision-making during the study.

Ages

18 to 34 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women undergoing in vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI). * Age younger than 35 years at the time of oocyte retrieval. * Good ovarian response, defined as having at least four good-quality embryos (Grade 1 or Grade 2) on Day 3 or later. * Undergoing the first or second IVF cycle. * Normal semen parameters of the male partner. * Willing to undergo non-invasive preimplantation genetic testing for aneuploidy (NiPGT-A) using spent embryo culture media. * Agree to vitrification of a single morphologically best-quality blastocyst and to undergo frozen single embryo transfer. * Able and willing to provide written informed consent. Exclusion Criteria: * Presence of untreated uterine abnormalities, including uterine malformations or significant intrauterine pathology. * History of uterine surgery. * History of ovarian surgery. * Known metabolic disorders. * Use of donor oocytes. * In vitro maturation (IVM) cycles. * Participation in another clinical study during the study period. * Patients who do not undergo frozen single embryo transfer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical pregnancy after single embryo transfer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • My Duc Hospital

    Ho Chi Minh City, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.